ArticleThoracic cancer2025
Impact of Interval to Esophagectomy After Neoadjuvant Immunochemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter Retrospective Cohort Analysis.
Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effectiveness comparison of pembrolizumab versus other immune checkpoint inhibitors in neoadjuvant chemoimmunotherapy for esophageal squamous cell carcinoma.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundNeoadjuvant chemoimmunotherapy (nICT) has emerged as a novel and promising treatment model for esophageal squamous cell carcinoma (ESCC). However, the optimal interval to esophagectomy after nICT remains unclear. This study aimed to explore the impact of a prolonged interval (7-10 weeks) on short- and long-term outcomes compared to the standard interval (4-6 weeks).
methodsThis was a multicenter retrospective cohort analysis, including three centers. Patients were diagnosed with locally advanced ESCC (cT3-4a or cN+) and received radical resection after at least one cycle of nICT. The primary outcomes were pathological response, disease-free survival (DFS), and overall survival (OS). Inverse probability of treatment weighting (IPTW) was utilized to balance the baseline characteristics.
resultsOne hundred and seventy patients were included in the study, with 123 in the standard interval group and 47 in the prolonged interval group. After IPTW, the prolonged interval group exhibited a higher pathological complete response (pCR) than the standard group, but the difference was not statistically significant (29.5% vs. 41.5%, p = 0.306). Additionally, although the 3-year DFS and OS rates were higher in the prolonged interval group, these differences did not reach statistical significance. There were no statistically significant variances observed in terms of intraoperative blood loss, surgical time, postoperative hospital stays, duration of thoracic drainage tube placement, hospital expenses, or postoperative complications.
conclusionsPatients demonstrated tolerance for esophagectomy within 4-6 weeks after nICT. Based on the present findings regarding pCR, DFS, and OS, extending the time to surgery beyond 6 weeks was found to be acceptable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.